Wordsmith.org : the magic of words

Thursday, August 31, 2017

Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

Novartis Institute for Tropical Diseases, (NITD), NIBR Singapore

The so called 'living drug' Tisagenlecleucel (aka Kymriah™ by Novartis) is a new CAR-T cell therapy = Docs say pricy gene-altering will violently attack, avert, and might cure harsh B-cell leukaemias
Anagram: Julian Lofts
Image: Novartis AG